Lineage Cell Therapeutics (LCTX) Net Income towards Common Stockholders (2010 - 2026)
Lineage Cell Therapeutics (LCTX) reported Net Income towards Common Stockholders of -$4.8 million for Q1 2026, up 20.16% on a YoY basis from -$4.0 million in Q1 2025, and down 129.76% quarter-over-quarter from $16.2 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$4.8 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 20.16% year-over-year to -$4.8 million; the trailing twelve-month figure through Mar 2026 stood at -$11.4 million (up 36.9% YoY), and the FY2025 full-year result was -$63.4 million, down 241.01% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$4.8 million, down from $16.2 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $16.2 million in Q4 2025, with the low at -$19.3 million in Q2 2025.
- Historically, Net Income towards Common Stockholders has averaged -$4.9 million across 5 years, with a median of -$5.6 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 389.85% — and 2025, when it surged 597.45%.
- Lineage Cell Therapeutics' Net Income towards Common Stockholders stood at -$6.4 million in 2022, then rose by 25.9% to -$4.7 million in 2023, then jumped by 31.06% to -$3.2 million in 2024, then surged by 597.45% to $16.2 million in 2025, then plunged by 129.76% to -$4.8 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$4.8 million (Q1 2026), $16.2 million (Q4 2025), and -$3.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | -4.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.81 Mn |
| Dec 31, 2025 | 16.17 Mn |
| Sep 30, 2025 | -3.42 Mn |
| Jun 30, 2025 | -19.33 Mn |
| Mar 31, 2025 | -6.03 Mn |
| Dec 31, 2024 | -3.25 Mn |
| Sep 30, 2024 | -3.00 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Mar 31, 2024 | -6.56 Mn |
| Dec 31, 2023 | -4.71 Mn |
| Sep 30, 2023 | -7.16 Mn |
| Jun 30, 2023 | -5.20 Mn |
| Mar 31, 2023 | -4.40 Mn |
| Dec 31, 2022 | -6.36 Mn |
| Sep 30, 2022 | -5.58 Mn |
| Jun 30, 2022 | -6.78 Mn |
| Mar 31, 2022 | -7.09 Mn |
| Dec 31, 2021 | -28.01 Mn |
| Sep 30, 2021 | -7.83 Mn |
| Jun 30, 2021 | -4.97 Mn |